Savara Inc. reported a net loss of $29.0 million, or $(0.13) per share, for the fourth quarter of 2024, compared to a net loss of $16.1 million, or $(0.09) per share, for the same period in 2023. For the full year 2024, the net loss was $95.9 million, or $(0.48) per share, an increase from $54.7 million, or $(0.33) per share, in 2023.
Research and development expenses increased by 76.3% to $78.0 million for the full year 2024, primarily due to $19.9 million related to chemistry, manufacturing, and controls activities for the MOLBREEVI program. General and administrative expenses rose by 59.8% to $25.0 million for the full year, driven by personnel costs and commercial preparation activities.
As of December 31, 2024, Savara held $196.3 million in cash, cash equivalents, and short-term investments. The company believes this cash position is sufficient to fund operations through the second quarter of 2027, excluding the recently secured debt financing of up to $200 million.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.